# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Douglas Tsao reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $12...
Needham analyst Ami Fadia reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $151 price target.
Oppenheimer analyst Francois Brisebois reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform and raises the p...
Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into th...
Needham analyst Ami Fadia maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $145...
HC Wainwright & Co. analyst Douglas Tsao reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $12...
Praxis Precision Medicines reports positive Phase 2 EMBOLD study results for relutrigine in treating SCN2A and SCN8A developmen...